Clinical trials: Small Cell Lung Cancer ( SCLC )
Lung Cancer
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061854
- Testing
- soblidotin
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC…
- Trial name
- NCT03799094
- Testing
- Vitamin C, Tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Carcinoma, Non-Small-Cell Lung
Personalized DC Vaccine for Lung Cancer
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
- Trial name
- SKLB1608 (NCT02956551)
- Testing
- DC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Non Small Cell Lung Cancer
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01746251
- Testing
- Afatinib
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- Massachusetts General Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
- Trial name
- NCT07172802
- Testing
- GI-108
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- GI Innovation, Inc.
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
This is a phase Ib study to evaluate safety and tolerability of dual checkpoint inhibition (DCI) of durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) with SBRT in the treatment of oligometastatic NSCLC.
- Trial name
- NCT03275597
- Testing
- Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Extensive Stage Small Cell Lung Cancer
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
This study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage SCLC who has clinical benefit from etoposide combined Los platinum (EL) scheme in the first line treatment.
- Trial name
- NCT02972320
- Testing
- temozolomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yunpeng Liu
Lung Cancer
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01059188
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 15 sites in Switzerland
- Volunteers
- 69 people
- Sponsor
- Swiss Cancer Institute
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
This is a phase II, single center, open label, multi-cohort platform study to identify a signature in tumor tissues, blood or stool that might help identify participants who are more likely to experience tumor shrinkage or side…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- DOME (NCT04262388)
- Testing
- Durvalumab, Oleclumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer
Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
Apatinib is a new kind of Vascular endothelial growth factor receptor(VEGFR) tyrosine kinase inhibitors (TKIs). The investigators have finished the preclinical and phase I and phase II clinical study for apatinib and found its…
- Trial name
- NCT01287962
- Testing
- apatinib
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab…
- Trial name
- NCT07098988
- Testing
- Visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2
- Where
- 51 sites in United States, Germany and 5 more
- Volunteers
- 107 people
- Sponsor
- CatalYm GmbH
Non Small Cell Lung Cancer
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ).
- Trial name
- METRIX (NCT06068842)
- Where
- 19 sites in Argentina, Brazil and 10 more
- Volunteers
- 579 people
- Sponsor
- AbbVie
Bladder Cancer, Cervical Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00790569
- Testing
- nicotine, varenicline
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Butler Hospital
Small Cell Lung Cancer
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)
This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT06612151
- Testing
- YL201, topotecan hydrochloride for injection
- Where
- China
- Volunteers
- 438 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable…
- Trial name
- NCT07323056
- Testing
- Sacituzumab Tirumotecan and Limertinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or radiation, or has spread to other parts of…
- Trial name
- NCT00901537
- Testing
- Azacitidine and Cisplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Lung Cancer, Nonsmall Cell, Lung Cancer
Trial of NanoPac Intratumoral Injection in Lung Cancer
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
- Trial name
- NCT04314895
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- NanOlogy, LLC
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Lung Cancer, Lung Adenocarcinoma
Identify Prognostic Biomarkers of Lung Cancer
Multi-omics and Clinical Data Analysis is potential to predict the prognosis of lung cancer patients.
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT05010330
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital